PHARNEXT Raises an Additional €8 Million for Its PleotherapyTM Platform Applied to the Treatment of Charcot-Marie Tooth Disease and Alzheimer's Disease
2/9/2012 6:50:15 AM
More...
|
PHARNEXT Has Completed Patient Recruitment for Its Phase II Clinical Trial of PXT3003 (the Company's First Pleodrug™) in Charcot-Marie-Tooth Disease
11/22/2011 10:42:23 AM
More...
|
PHARNEXT Announces a €2.5 Million Round of Financing
9/8/2011 6:48:38 AM
More...
|
PHARNEXT Receives Clinical Trial Authorization for a Phase II Study with the First Drug Generated by Its Pleotherapy(TM) Technology
12/3/2010 8:50:25 AM
More...
|
OSEO Awards a €10.4 Million Funding Package to PHARNEXT, BioSystems International, Bordeaux Hospital (CMRR1), University Bordeaux Segalen and INSERM
11/18/2010 2:09:43 PM
More...
|
PHARNEXT Raises Eur 4.8 Million Series A Funding
6/9/2010 6:57:32 AM
More...
|
Ipsen and PHARNEXT Conclude an Exclusive Research, Development and Marketing Agreement
6/15/2009 10:03:31 AM
More...
|